Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$30.27 - $43.79 $2.2 Million - $3.19 Million
-72,768 Reduced 92.0%
6,331 $204,000
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $8.37 Million - $11.8 Million
-267,297 Reduced 77.17%
79,099 $3.33 Million
Q3 2023

Nov 14, 2023

SELL
$18.55 - $39.96 $12.3 Million - $26.5 Million
-663,087 Reduced 65.69%
346,396 $13.3 Million
Q2 2023

Aug 14, 2023

BUY
$14.2 - $23.75 $519,904 - $869,558
36,613 Added 3.76%
1,009,483 $19.1 Million
Q1 2023

May 15, 2023

BUY
$15.27 - $19.72 $9.4 Million - $12.1 Million
615,833 Added 172.48%
972,870 $15.1 Million
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $648,917 - $1.75 Million
98,470 Added 38.08%
357,037 $6.34 Million
Q3 2022

Nov 14, 2022

SELL
$3.93 - $6.37 $1.15 Million - $1.86 Million
-291,816 Reduced 53.02%
258,567 $1.44 Million
Q2 2022

Aug 15, 2022

SELL
$3.38 - $5.65 $917,622 - $1.53 Million
-271,486 Reduced 33.03%
550,383 $2.15 Million
Q1 2022

May 16, 2022

SELL
$5.06 - $8.77 $160,194 - $277,649
-31,659 Reduced 3.71%
821,869 $4.53 Million
Q4 2021

Feb 14, 2022

SELL
$7.33 - $9.32 $2.13 Million - $2.71 Million
-290,783 Reduced 25.41%
853,528 $7.27 Million
Q3 2021

Nov 15, 2021

SELL
$7.01 - $11.37 $917,174 - $1.49 Million
-130,838 Reduced 10.26%
1,144,311 $9.94 Million
Q2 2021

Aug 16, 2021

BUY
$9.4 - $16.85 $4.74 Million - $8.5 Million
504,584 Added 65.48%
1,275,149 $13.5 Million
Q1 2021

May 17, 2021

BUY
$13.08 - $49.6 $9.65 Million - $36.6 Million
737,829 Added 2253.88%
770,565 $12.4 Million
Q4 2020

Feb 16, 2021

SELL
$36.36 - $52.71 $1 Million - $1.46 Million
-27,609 Reduced 45.75%
32,736 $1.51 Million
Q3 2020

Nov 16, 2020

BUY
$22.61 - $38.9 $1.16 Million - $1.99 Million
51,198 Added 559.72%
60,345 $2.12 Million
Q2 2020

Aug 14, 2020

BUY
$13.87 - $28.44 $126,868 - $260,140
9,147 New
9,147 $223,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.